Showing Results for
- Academic Journals (30)
Search Results
- 30
Academic Journals
- 30
- Search Terms:
- 1From: Leukemia. (Vol. 28, Issue 7) Peer-ReviewedTherapeutic regimens for chronic lymphocytic leukemia (CLL) have increasingly utilized monoclonal antibodies since the chimeric anti-CD20 antibody rituximab was introduced. Despite improved clinical outcomes, current CLL...
- 2From: Leukemia. (Vol. 28, Issue 7) Peer-ReviewedMajor changes have taken place within the last few years in the management of follicular lymphoma (FL) leading to substantial improvement in prognosis and overall survival. For some patients with limited disease stages I...
- 3From: Leukemia. (Vol. 28, Issue 7) Peer-ReviewedInhibitor of Apoptosis (IAP) proteins exert essential functions during tumorigenesis as well as treatment resistance by simultaneously blocking cell death pathways and promoting cell survival. As IAP proteins are...
- 4From: Leukemia. (Vol. 28, Issue 7) Peer-ReviewedCalreticulin (CALR) is a multifunctional [Ca.sup.2+] -binding protein located in the endoplasmic reticulum. CALR mutations are recurrent in JAK2/MPL-unmutated essential thrombocythemia (ET) and primary myelofibrosis...
- 5From: Leukemia. (Vol. 28, Issue 7) Peer-ReviewedMultiple myeloma (MM) incidence is markedly higher in blacks compared with whites, which may be related to a higher prevalence of monoclonal gammopathy of undetermined significance (MGUS). Our objective was to AA define...
- 6From: Leukemia. (Vol. 28, Issue 7) Peer-ReviewedJuvenile myelomonocytic leukemia (JMML) is a fatal, mixed myeloproliferative and myelodysplastic disorder occurring in infancy and early childhood. Children with JMML have mutually exclusive genetic abnormalities in...
- 7From: Leukemia. (Vol. 28, Issue 7) Peer-ReviewedAcute myeloid leukemia (AML) is a malignant disease of cells arising from the myeloid lineage. As a heterogeneous disease, AML consists of many different subtypes, each with different treatment sensitivities and...
- 8From: Leukemia. (Vol. 28, Issue 7) Peer-ReviewedIn this open-label, intra-patient phase I/II trial, bortezomib was replaced with carfilzomib (escalated from 20 to 45 mg/[m.sup.2] on days 1, 2, 8, 9, 15 and 16 of a 28-day cycle) for multiple myeloma (MM) patients who...
- 9From: Leukemia. (Vol. 28, Issue 7) Peer-ReviewedWithin pediatric MLL-rearranged acute myeloid leukemia (AML), the translocation partners have been shown to be clinically highly relevant. (1) The most striking example is the t(6;11)(q27;q23) subtype, which has an...
- 10From: Leukemia. (Vol. 28, Issue 7) Peer-ReviewedMixed-lineage leukemia fusion proteins activate their target genes predominantly by stimulating transcriptional elongation. A core component necessary for this activity is cyclin-dependent kinase 9. Here we explored the...
- 11From: Leukemia. (Vol. 28, Issue 7) Peer-ReviewedThe inhibitor of apoptosis (IAP) proteins have a critical role in the control of apoptotic machinery, and has been explored as a therapeutic target. Here, we have examined the functional importance of IAPs in multiple...
- 12From: Leukemia. (Vol. 28, Issue 7) Peer-ReviewedOleoylethanolamide (OEA) is a bioactive lipid that stimulates nuclear and G protein-coupled receptors and regulates appetite and fat metabolism. It has not previously been shown to have a role in cancer. However, a mass...
- 13From: Leukemia. (Vol. 28, Issue 7) Peer-ReviewedHematopoiesis is a tightly regulated process involving the control of gene expression that directs the transition from hematopoietic stem and progenitor cells to terminally differentiated blood cells. In leukemia, the...
- 14From: Leukemia. (Vol. 28, Issue 7) Peer-ReviewedPulmonary hypertension (PH) is a frequently under recognized complication of myelofibrosis (MF). The pathophysiology of PH in MF is unknown and no definitive therapies have been established. We studied 15 patients with...
- 15From: Leukemia. (Vol. 28, Issue 7) Peer-ReviewedRecently, somatic mutations in exon 9 of calreticulin (CALR) were detected in patients with myeloproliferative neoplasms (MPN) who had nonmutated JAK2 and MPL. (1,2) Similar genetic alterations, such as mutations of...
- 16From: Leukemia. (Vol. 28, Issue 7) Peer-ReviewedThe last decade has seen significant advances in the management of patients with multiple myeloma (MM). With increasingly effective therapies, MM patients are living longer. With improvements in survival, long-term...
- 17From: Leukemia. (Vol. 28, Issue 7) Peer-ReviewedNearly all human cancers are preceded by precursor states far more prevalent than clinical malignancy itself. Understanding which premalignant lesions are truly biologically premalignant versus those with impending...
- 18From: Leukemia. (Vol. 28, Issue 7) Peer-ReviewedCalreticulin (CALR) mutations were recently described in JAK2 and MPL unmutated primary myelofibrosis (PMF) and essential thrombocythemia. In the current study, we compared the clinical, cytogenetic and molecular...
- 19From: Leukemia. (Vol. 28, Issue 7) Peer-ReviewedSorafenib is a multikinase inhibitor and a potent FLT3 inhibitor that inhibits tumor growth and angiogenesis by inhibiting intracellular Raf kinases and cell surface kinase receptors such as VEGFR, PDGFR-[beta], cKIT...
- 20From: Leukemia. (Vol. 28, Issue 7) Peer-ReviewedMyeloperoxidase (MPO) has been associated with both a myeloid lineage commitment and favorable prognosis in patients with acute myeloid leukemia (AML). DNA methyltransferase inhibitors (decitabine and zeburaline)...